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Inﬂammation is an essential component of pathogenesis and progression of cancer. A high
neutrophil-to-lymphocyte ratio (NLR) is considered as a prognostic indicator for breast cancer.
This meta-analysis was conducted to establish the overall accuracy of the NLR test in the diagnosis
of breast cancer. A comprehensive search of the literature was conducted by using PubMed, Web of
Science and China National Knowledge Infrastructure (CNKI). Published studies dating up to July
2014 and 4,293 patients were enrolled in the present study. In order to evaluate the association
between NLR and overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS)
or cancer speciﬁc survival (CSS), the hazard ratios (HRs) and their 95% conﬁdence intervals (CIs)
were extracted. OS was the primary outcome. The results suggested that increased NLR was a strong
predictor for OS with HR of 2.28 (95% CI = 1.08–4.80, Pheterogeneity < 0.001). Stratiﬁed analyses indi-
cated that a high NLR appeared to be a negative prognostic marker in Caucasian populations
(HR = 4.53, 95% CI = 3.11–6.60, Pheterogeneity = 0.096), multivariate analysis method (HR = 2.10,
95% CI = 1.52–2.89, Pheterogeneity = 0.591), and mixed metastasis (HR = 4.53, 95% CI = 3.11–6.60,
Pheterogeneity = 0.096). Elevated NLR was associated with a high risk for DFS (HR = 1.38,
95% CI = 1.09–1.74, Pheterogeneity = 0.050) and in subgroups of multivariate analysis (HR = 1.64,
95% CI = 1.25–2.14, Pheterogeneity = 0.545) and mixed metastasis (HR = 1.99, 95% CI = 1.28–3.09,
Pheterogeneity = 0.992). In summary, NLR could be considered as a predictive factor for patients with
breast cancer.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction and metastasis and to identify effective early-diagnostic andBreast cancer is a common malignancy that affects the health of
women worldwide. One in eight women will be diagnosed with
breast cancer in their lifetime [1]. 5–7% of women are diagnosed
before the age of 40, and the highest frequency is found in the
age group 25 to 39 [2–5]. With the rapid advancement of early
diagnosis and treatment in breast cancer, more than four ﬁfths of
patients are now successfully treated [4] and the mortality has
recently declined in young women [6]. However, a large proportion
of patients were still suffered from breast cancer due to hetero-
geneity of diagnosis and treatment. Therefore, it is crucial to
understand causes contributing to breast carcinogenesis, invasionprognostic biomarkers that help to diagnose, evaluate treatment
efﬁcacy and prognosis and follow-up schedule [7].
It has been demonstrated that the inﬂammatory response plays
an important role in the development and progression of various
cancers, including breast cancer [8–10]. The cancer-related inﬂam-
matory response helps proliferation and survival of malignant
cells, angiogenesis and metastasis of breast cancer, and it subverts
adaptive immune responses and alters responses to chemothera-
peutic agents. Severe inﬂammatory responses result in a weaker
adaptive immune response, leading to an imbalance of immune
response and malignant cancer to promote cancer progression
and poor OS.
Biomarkers such as neutrophils, lymphocytes, neutrophil-
to-lymphocyte ratio (NLR), mean platelet volume, red cell
distribution width, circulating tumor cells and gamma-glutamyl
transferase have been proposed as potential prognostic factors
for cancer [11–15]. There is accumulating evidence for the
association of NLR with survival of patients with many kinds of
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results are inconsistent. Some studies reported that NLR was sig-
niﬁcantly associated with shorter DFS and OS in breast cancer
patients [24,25], while others showed that NLR could not be con-
sidered as an independent prognostic factor for breast cancer
[26,27].
In order to obtain an objective and consistent conclusion, we
therefore conducted this comprehensive systematic review and
meta-analysis of the association between NLR and survival of
breast cancer.
2. Materials and methods
2.1. Search strategy
This meta-analysis was conducted according to Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement and methods [28,29]. A comprehensive
literature search was carried out using search terms of
‘‘neutrophil-to-lymphocyte ratio (NLR)’’, ‘‘breast cancer or tumor
or carcinoma’’ and ‘‘prognosis or outcome or survival’’ in databases
of PubMed, Web of Science and CNKI dating up to July 2014. Hand
searches were performed to obtain substantial relevant study by
reviewing all references within all relevant articles. All selected lit-
eratures were journal articles in Chinese and English. This study
was approved by the institution ethics committee of Nanjing
Normal University.
2.2. Selection criteria
In the meta-analysis, studies were considered eligible if they
met the following criteria: (1) study investigated the association
between NLR and clinical prognosis in patients with breast cancer;
(2) study provided sufﬁcient data for estimating hazard ratio (HR)
with 95% conﬁdence interval (CI). Meanwhile, studies were
excluded based on the following criteria: (1) duplicate publica-
tions; (2) insufﬁcient data for further analysis; (3) letters, reviews,
meeting abstracts, editorials, and case reports; (4) other topics.
2.3. Data extraction
The following data, the ﬁrst author, year of publication, name of
journal, county of origin, ethnicity of the study population, type of
specimen, metastasis, cut-off value, follow-up period, number of
patients included in analysis, and HR with its 95% CI for overall sur-
vival (OS), disease-free survival (DFS), recurrence-free survival
(RFS) or cancer speciﬁc survival (CSS) were extracted from each eli-
gible study by two independent investigators (JC, QWD). If there
was any disagreement, it solved by discussion to reach a
consensus.
2.4. Statistical analysis
HR and its 95 % CI were selected as common measurements to
assess the strength of the association between NLR and prognosis
in breast cancer. Cochran’s Q test was chosen to evaluate the
heterogeneity and Higgins I-squared statistic was carried out to
estimate the degree of heterogeneity of pooled results. The
random-effect and ﬁxed-effect models were used to calculate the
pooled HR and its 95% CI. If PH < 0.05, the random-effect model
(DerSimonian–Laird method) was applied to calculate the pooled
HRs [30]. Otherwise, the ﬁxed-effect model (Mantel–Haenszel
method) was employed [31]. The HR is commonly and conve-
niently estimated via a Cox proportional hazards model, which
can include potential confounders as covariates. HR > 1 reﬂectsthat elevated NLR is associated with the corresponding variate,
while HR < 1 has the opposite meaning. Furthermore, subgroup
was performed to explore the heterogeneity among studies which
stratiﬁed by ethnicity, analysis method and metastasis. Sensitivity
analysis was conducted to check whether individual study inﬂu-
enced the results by sequential omission of each study in this
meta-analysis. Additionally, Begg’s funnel plot and Egger’s linear
regression test were used to assess the extent of publication bias
in the meta-analysis and PE < 0.05 was considered as statistically
signiﬁcant. Statistical analysis was performed by Stata 11.0 soft-
ware (STATA Corporation, College Station, TX, USA).
3. Results
3.1. Included studies
A total of 45 potentially relevant articles were retrieved. 14
papers were deﬁned duplicate publications according to their
titles. Then 20 articles were excluded because of obvious lack of
relevance. A careful review of the remaining 11 studies revealed
that 3 studies did not provide sufﬁcient information. Finally,
8 studies were included in the meta-analysis (Fig. 1) [16,22–25,
27,32,33].
3.2. Study characteristics
The main features of eligible studies were shown in Table 1. The
eligible studies were published in a period of 2012 to 2014 and
contained a total of 4,293 patients. In total, 8 studies were enrolled
and 4 studies were conducted in Asian and Caucasian population,
respectively. 5 studies were involved in mixed metastasis and
the others without metastasis. The cut-off values applied in the
studies were not consistent and it was not provided in one study
[16]. Among them, 5, 4, 1 and 1 studies investigated the relation-
ship of NLR and OS, DFS, RFS, and CSS, respectively. The useful data
of HRs and 95% CIs were obtained from multivariate analysis in 5
studies and univariate analysis in 3 studies, respectively.
3.3. Overall survival
The pooled analysis was conducted in 5 studies including 3,350
patients that reported HR for OS. The main results of this
meta-analysis were listed in Table 2 and Fig. 2. The results showed
that elevated NLR was associated with a worse outcome for OS
with the pooled HR of 2.28 (95% CI = 1.08–4.80, PH < 0.001).
Subgroup analyses showed that the prognostic effect of NLR
was found only in Caucasian population (HR = 4.53, 95% CI =
3.11–6.60, PH = 0.096) and it was examined to be was a strong
prognostic factor in multivariate analysis (HR = 2.10, 95%
CI = 1.52–2.89, PH = 0.591). When metastasis was taken into con-
sideration, increased NLR was associated with a poor prognosis
for OS in mixed metastasis (HR = 4.53, 95% CI = 3.11–6.60,
PH = 0.096).
From sensitivity analysis we found that the result was not obvi-
ously impacted by an included study conducted by Cihan et al.
[27]. The HR for it was 3.08 (95% CI = 1.59–5.96, PH = 0.002). The
shape of funnel plots showed no evidence of publication bias in
the analysis (Fig. 3) and the result was further supported by
Egger’s tests (PE = 0.896).
3.4. Disease-free survival
4 studies comprising 2,764 patients were included to assess the
association between NLR and DFS in breast cancer (Table 2).
Overall, elevated NLR was associated with a high risk for DFS
Fig. 1. Flow diagram of studies included in this meta-analysis.
Table 1
Main characteristics of eligible studies.
No. of
studies
First author Journal Year Country Ethnicity Specimens Metastasis Cut-
off
Follow-up
(month)
Number
of
patients
Analysis Survival HR
estimation
[16] Forget P Ann Surg
Oncol
2013 Belgium Caucasian Blood Mix 3.4 NA 162,172 Univariate RFS HR + 95% CI
[22] Azab B Ann Surg
Oncol
2012 USA Caucasian Blood Mix 3.3 45.6(mean) 316 Multivariate OS HR + 95% CI
[23] Noh H J Breast
Cancer
2013 Korea Asian Blood No 2.5 6.1(mean) 442 Multivariate CSS HR + 95% CI
[24] Forget P Br J Anaesth 2014 Belgium Caucasian Blood Mix 3.3 69.8(median) 720 Multivariate OS,DFS HR + 95% CI
[25] Dirican A Int J Clin
Oncol
2014 Turkey Asian Blood No 4 30(median) 1,527 Multivariate OS,DFS HR + 95% CI
[27] Cihan YB Asian Pac J
Cancer Prev
2014 Turkey Asian Blood No 3 Mean range
10 days-
112 months
350 Univariate OS,DFS HR + 95% CI
[32] Azab B Med Oncol 2013 USA Caucasian Blood Mix 3.3 60(mean) 437 Univariate OS HR + 95% CI
[33] Nakano K Anticancer
Res
2014 Japan Asian Blood Mix 2.5 85.8(mean) 167 Multivariate DFS HR + 95% CI
NA: not available; DFS: disease-free survival; OS: overall survival; RFS: recurrence-free survival; CSS: cancer-speciﬁc survival; HR: hazard ratio; CI: 95% conﬁdence interval.
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multivariate analysis (HR = 1.64, 95% CI = 1.25–2.14, PH = 0.545)
and mixed metastasis (HR = 1.99, 95% CI = 1.28–3.09, PH = 0.992).
Interestingly, the same study [27] had no effect on sensitivity
analysis by removing one study each time. The HR for it was 1.64
(95% CI = 1.25–2.14, PH < 0.001). The rest studies [24,25,27,33]
might be source of heterogeneity. The Begg’s funnel plot (Fig. 4)
and the Egger’s test (P = 0.762) did not provide any obvious
evidence of publication bias.
4. Discussion
Inﬂammation has been shown to be an important factor in the
development of tumorigenesis [34]. Peripheral blood tests before
treatment or at the time of diagnosis could reﬂect inﬂammatoryconditions within the tumor. Inﬂammation-related markers such
as absolute white blood cell count, C-reactive protein (CRP), cytoki-
nes, platelet-to-lymphocyte ratio (PLR), and NLR have been shown
to be associated with speciﬁc outcomes in cancer patients [35].
NLR is a biomarker for inﬂammation and it can be more easily
and conveniently measured than conventional markers and at a
low cost. A meta-analysis recently reported by Templeton et al.
[35] only included 3 original studies and did not show a signiﬁcant
correlation between NLR and survival of breast cancer. The current
meta-analysis combined the outcomes of 4,293 cancer patients
from 8 studies was to assess the prognostic effect of NLR in breast
cancer. In this meta-analysis, we found that high level of NLR sig-
niﬁcantly affected OS and DFS in breast cancer in overall popula-
tion. When groups were stratiﬁed by ethnicity, analysis method
and metastasis, elevated NLR predicted poor OS in Caucasian
Table 2
Meta-analysis results.
Survival Variables Number of studies Number of patients P value Regression model
PH PZ PE Random Fixed
OS All 5 3,350 <0.001 0.031 0.894 2.28(1.08–4.80) 2.36(1.85–3.02)
Ethnicity <0.001
Asian 2 1,877 0.007 0.723 — 1.19(0.45–3.19) 1.46(1.06–2.02)
Caucasian 3 1,473 0.096 <0.001 — 3.89(2.05–7.39) 4.53(3.11–6.60)
Analysis method 0.263
Univariate 2 787 <0.001 0.495 — 2.11(0.25–17.88) 2.79(1.91–4.07)
Multivariate 3 2,563 0.591 <0.001 — 2.10(1.52–2.89) 2.10(1.52–2.89)
Metastasis <0.001
No 2 1,877 0.007 0.723 — 1.19(0.45–3.19) 1.46(1.06–2.02)
Mix 3 1,473 0.096 <0.001 — 3.89(2.05–7.39) 4.53(3.11–6.60)
DFS All 4 2,764 0.050 0.093 0.762 1.41(0.94–2.12) 1.38(1.09–1.74)
Ethnicity 0.141
Asian 3 2,044 0.06 0.328 — 1.27(0.78–2.06) 1.27(0.98–1.64)
Caucasian 1 720 — 0.012 — 1.99(1.16–3.41) 1.99(1.16–3.41)
Analysis method 0.010
Univariate 1 350 — 0.360 — 0.80(0.50–1.29) 0.80(0.50–1.29)
Multivariate 3 2,414 0.545 <0.001 — 1.64(1.25–2.14) 1.64(1.25–2.14)
Metastasis 0.053
No 2 1,877 0.044 0.732 — 1.11(0.62–1.99) 1.20(0.91–1.57)
Mix 2 887 0.992 0.002 — 1.99(1.28–3.09) 1.99(1.28–3.09)
OS: overall survival; DFS: disease-free survival; PH, P value of heterogeneity test; PZ, P value of Z test; PE, P value of Egger’s test.
Fig. 2. Forest plots of studies evaluating hazard ratios (HRs) of NLR for overall survival. The solid diamond represents each individual study and the hollow diamond
represents overall studies. Error bars are 95% conﬁdence intervals.
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tively. Meanwhile, the signiﬁcant association was observed in mul-
tivariate analysis, and mixed metastasis subgroups in DFS. These
ﬁndings indicated that NLR was associated with ethnicity, analysis
methods and metastasis and it could act as a prognostic biomarker
in predicting clinical outcome for breast cancer.
The mechanism between the high level of NLR and poor out-
come of breast cancer remained unclear. There were several possi-
ble explanations for the association between elevated NLR and
poor prognosis in breast cancer. First of all, their relationship mightbe explained by means of an inﬂammation response caused by
cancer cells. As is known, lymphocytes can reduce malignant pro-
gression as tumor inﬁltration via a series of subtypes of lympho-
cytes, CD3+ T cells, CD8+ T cells, Th1 CD4+ T cell, and p46+
natural killer cells, which has been shown to improve the survival
of patients with malignancy [36–39]. An important event of
immune escape was T-lymphocyte dysfunction. T-lymphocytes
were a common kind of tumor inﬁltrating lymphocytes (TILs). A
study suggested that anergic CD8+ T-lymphocytes were function-
ally unresponsive, unable to directly lyse melanoma target cells
Fig. 3. Begg’s funnel plot assessed publication bias test of the included studies for
overall survival (OS). Each circle represents as an independent study for the
indicated association. Log[HR], natural logarithm of HR. Horizontal lines mean
effect size. HR: hazard ratio.
Fig. 4. Begg’s funnel plot assessed publication bias test of the included studies for
disease-free survival (DFS). Each circle represents as an independent study for the
indicated association. Log[HR], natural logarithm of HR. Horizontal lines mean
effect size. HR: hazard ratio.
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genic tumor variants would take place when tumor cells were able
to escape from immune surveillance. Another explanation was that
IL-17 could recruit neutrophil via CXC chemokines, such as CCL2
released from IL-17-producing T cell. Therefore, IL-17-producing
T cells released CXC chemokines that recruited neutrophils, leading
to elevated NLR.
To the best of our knowledge, it is the largest sample size of
meta-analysis to investigate the prognostic role of NLR in breast
cancer. Several strong points and limitations should be addressed
as follow: this is the ﬁrst study to investigate the association
between NLR and survival of breast cancer; furthermore, hetero-
geneity test was conducted to conﬁrm the outcomes of subgroup
analyses and explore sources of heterogeneity; ﬁnally, there was
almost no publication bias in this meta-analysis, showing the
results were reliable. However, ﬁrst of all, only summarized data
rather than individual patient data were pooled in our study,
which might preclude us from conducting a more in-depth analy-
sis; secondly, even though we used prospectively listed patients
and high-quality databases, uncontrolled and unrecognized biases
might exist; thirdly, geographical differences in the frequency of
breast cancer subtypes might have been obscured by the lack of
standardization in pre-analytical and analytical procedures across
studies, and these differences were also a potential source ofheterogeneity; ﬁnally, due to lack of appropriate data, the associa-
tion of NLR and other clinical parameters, such as mean platelet
volume, red cell distribution width, circulating tumor cells and
gamma-glutamyl transferase was not explored. Thus, more world-
wide studies are required to conﬁrm the value of the NLR test for
breast cancer diagnosis in the future.
In conclusion, elevated NLR is strongly associated with poor
survival of breast cancer patients, and it can be regarded as a pre-
dictive and prognostic factor for patients with breast cancer.
Further well designed prospective studies with multi-central and
a large sample size are warrant to verify our ﬁndings.
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